{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:06:54Z","timestamp":1787256414014,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.pbb.2014.06.008","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T15:18:20Z","timestamp":1403277500000},"page":"245-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT1A receptors"],"prefix":"10.1016","volume":"124","author":[{"given":"Noriko","family":"Yoshimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Ohgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Futamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2014.06.008_bb0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/026988110101500108","article-title":"The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?","volume":"15","author":"Bantick","year":"2001","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pbb.2014.06.008_bb0010","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/026988110401800304","article-title":"A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment","volume":"18","author":"Bantick","year":"2004","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pbb.2014.06.008_bb0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bbr.2008.06.011","article-title":"Molecular imaging of the 5-HT1A receptor in relation to human cognition","volume":"195","author":"Borg","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2014.06.008_bb0025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/acps.12133","article-title":"Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis","volume":"128","author":"Bourne","year":"2013","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pbb.2014.06.008_bb0030","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0893-133X(96)00053-X","article-title":"5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia","volume":"15","author":"Burnet","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2014.06.008_bb0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00213-003-1709-2","article-title":"The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia","volume":"174","author":"Coyle","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2014.06.008_bb0040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/npp.2012.179","article-title":"An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans","volume":"38","author":"Dean","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2014.06.008_bb0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-006-0543-8","article-title":"Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY-100,635","volume":"189","author":"Frankle","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2014.06.008_bb0050","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMra035458","article-title":"Schizophrenia","volume":"349","author":"Freedman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pbb.2014.06.008_bb0055","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.pnpbp.2007.08.031","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline","volume":"32","author":"Fujita","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pbb.2014.06.008_bb0065","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","article-title":"Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria","volume":"56","author":"Green","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2014.06.008_bb0070","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0006-3223(97)00321-1","article-title":"Alterations in the cortical serotonergic system in schizophrenia: a postmortem study","volume":"42","author":"Gurevich","year":"1997","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2014.06.008_bb0080","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.euroneuro.2007.11.005","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptor","volume":"18","author":"Hagiwara","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pbb.2014.06.008_bb0075","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1399-5618.2010.00831.x","article-title":"Cognition and disability in bipolar disorder: lessons from schizophrenia research","volume":"12","author":"Harvey","year":"2010","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.pbb.2014.06.008_bb0115","first-page":"147","article-title":"Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs","volume":"4","author":"Hashimoto","year":"2004","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.pbb.2014.06.008_bb0100","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2005.07.002","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol","volume":"519","author":"Hashimoto","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2014.06.008_bb0120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/1573400054065569","article-title":"Dysfunction of glia-neuron communication in pathophysiology of schizophrenia","volume":"1","author":"Hashimoto","year":"2005","journal-title":"Curr Psychiatry Rev"},{"key":"10.1016\/j.pbb.2014.06.008_bb0085","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejphar.2006.09.055","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of \u03b17 nicotinic receptors","volume":"553","author":"Hashimoto","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2014.06.008_bb0095","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.npp.1301047","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors","volume":"32","author":"Hashimoto","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2014.06.008_bb0090","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.euroneuro.2007.07.009","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of glycine transporter-1 inhibitor NFPS","volume":"18","author":"Hashimoto","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pbb.2014.06.008_bb0105","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.biopsych.2007.04.034","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective \u03b17 nicotinic receptor agonist SSR180711","volume":"63","author":"Hashimoto","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2014.06.008_bb0110","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00406-013-0399-y","article-title":"Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders","volume":"263","author":"Hashimoto","year":"2013","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.pbb.2014.06.008_bb0125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jad.2010.11.011","article-title":"Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review","volume":"134","author":"Hasselbalch","year":"2011","journal-title":"J Affect Disord"},{"key":"10.1016\/j.pbb.2014.06.008_bb0130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0924-977X(97)00050-3","article-title":"The role of N-methyl-d-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes","volume":"8","author":"Heresco-Levy","year":"1998","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pbb.2014.06.008_bb0135","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hup.1106","article-title":"Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered","volume":"25","author":"Hindmarch","year":"2010","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.pbb.2014.06.008_bb0140","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pbb.2014.06.008_bb0145","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/schbul\/sbs069","article-title":"Has an angel shown the way? Etiological and therapeutic implications of the PCP\/NMDA model of schizophrenia","volume":"38","author":"Javitt","year":"2012","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pbb.2014.06.008_bb0150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2014.06.008_bb0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2014.06.008_bb0160","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/npp.1993.32","article-title":"Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenia","volume":"8","author":"Joyce","year":"1993","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2014.06.008_bb0170","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/hrp.7.3.125","article-title":"NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders","volume":"7","author":"Krystal","year":"1999","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.pbb.2014.06.008_bb0175","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.brainres.2009.05.004","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of donepezil: role of sigma-1 receptors","volume":"1279","author":"Kunitachi","year":"2009","journal-title":"Brain Res"},{"key":"10.1016\/j.pbb.2014.06.008_bb0180","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.biopsych.2003.09.017","article-title":"Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia","volume":"55","author":"Lopez-Figueroa","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2014.06.008_bb0185","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"issue":"2 Suppl","key":"10.1016\/j.pbb.2014.06.008_bb0195","doi-asserted-by":"crossref","first-page":"106S","DOI":"10.1016\/S0893-133X(99)00046-9","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2014.06.008_bb0200","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbr.2008.05.016","article-title":"Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?","volume":"195","author":"Meltzer","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2014.06.008_bb0210","first-page":"802","article-title":"The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspective","volume":"11","author":"Newman-Tancredi","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.pbb.2014.06.008_bb0205","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-2999(01)01344-9","article-title":"Efficacy of antipsychotic agents at human 5-HT1A receptors determined by [3H]WAY-100,635 binding affinity ratios: relationship to efficacy for G-protein activation","volume":"428","author":"Newman-Tancredi","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2014.06.008_bb0215","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2174\/138161212799436476","article-title":"Sigma-1 receptor agonists as therapeutic drugs for cognitive impairments in neuropsychiatric disease","volume":"18","author":"Niitsu","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pbb.2014.06.008_bb0220","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbr.2008.02.023","article-title":"The role of 5-HT1A receptors in learning and memory","volume":"195","author":"Ogren","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2014.06.008_bb0225","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1192\/bjp.182.3.214","article-title":"Neurocognitive impairment in drug-free patients with major depressive disorder","volume":"182","author":"Porter","year":"2003","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pbb.2014.06.008_bb0230","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.2174\/1381612819666131216114240","article-title":"The novel object recogniton test in rodents in relation to cognitive impairment in schizophrenia","volume":"20","author":"Rajagopal","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pbb.2014.06.008_bb0235","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0006-3223(00)00850-7","article-title":"5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex","volume":"48","author":"Rollema","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2014.06.008_bb0240","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0893-133X(99)00057-3","article-title":"Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation","volume":"21","author":"Sprouse","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2014.06.008_bb0245","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1176\/appi.ajp.158.10.1722","article-title":"Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment","volume":"158","author":"Sumiyoshi","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pbb.2014.06.008_bb0250","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0006-3223(00)01025-8","article-title":"The effect of tandospirone, a serotonin-1A agonist, on memory function in schizophrenia","volume":"49","author":"Sumiyoshi","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2014.06.008_bb0260","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.schres.2007.06.008","article-title":"Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"95","author":"Sumiyoshi","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pbb.2014.06.008_bb0255","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fnbeh.2013.00140","article-title":"Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia","volume":"7","author":"Sumiyoshi","year":"2013","journal-title":"Front Behav Neurosci"},{"key":"10.1016\/j.pbb.2014.06.008_bb0265","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.euroneuro.2009.07.005","article-title":"Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: a possible role of adrenergic \u03b11 receptors","volume":"19","author":"Tanibuchi","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pbb.2014.06.008_bb0270","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archpsyc.59.6.514","article-title":"Brain serotonin 5-HT1A receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100,635","volume":"59","author":"Tauscher","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pbb.2014.06.008_bb0275","doi-asserted-by":"crossref","first-page":"e42676","DOI":"10.1371\/journal.pone.0042676","article-title":"Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder","volume":"7","author":"Yoshida","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2014.06.008_bb0280","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2174\/1573400511208020140","article-title":"Recent advances in the potential therapeutic drugs for cognitive deficits in schizophrenia","volume":"8","author":"Yoshida","year":"2012","journal-title":"Curr Psychiatry Rev"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305714001786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305714001786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T06:26:03Z","timestamp":1538547963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305714001786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":52,"alternative-id":["S0091305714001786"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2014.06.008","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT1A receptors","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2014.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}